Alnylam Pharmaceuticals (ALNY) Other Non-Current Assets (2011 - 2026)

Alnylam Pharmaceuticals has reported Other Non-Current Assets for 14 years, with the latest figure at $63.6 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets fell 13.91% year-over-year to $63.6 million; the trailing twelve-month figure through Mar 2026 stood at $63.6 million (down 13.91% YoY), and the FY2025 full-year result was $59.5 million, down 8.96% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $63.6 million, up from $59.5 million in the prior quarter.
• The five-year high for Other Non-Current Assets was $92.7 million in Q2 2023, with the low at $55.8 million in Q3 2025.
• Historically, Other Non-Current Assets has averaged $68.2 million across 5 years, with a median of $66.1 million in 2022.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets surged 123.4% — and 2025, when it fell 28.06%.
• Alnylam Pharmaceuticals' Other Non-Current Assets stood at $66.1 million in 2022, then decreased by 6.34% to $61.9 million in 2023, then rose by 5.51% to $65.3 million in 2024, then fell by 8.96% to $59.5 million in 2025, then rose by 6.88% to $63.6 million in 2026.
• The last three Other Non-Current Assets figures came in at $63.6 million (Q1 2026), $59.5 million (Q4 2025), and $55.8 million (Q3 2025), per Business Quant data.